Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1993 2
1994 5
1995 5
1996 1
1997 2
1998 3
2001 2
2002 9
2003 6
2004 1
2005 1
2006 2
2007 6
2008 4
2009 4
2010 3
2012 2
2014 1
2017 2
2019 2
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Hochhaus A, et al. Among authors: o brien sg. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324. N Engl J Med. 2017. PMID: 28273028 Free PMC article. Clinical Trial.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators. O'Brien SG, et al. N Engl J Med. 2003 Mar 13;348(11):994-1004. doi: 10.1056/NEJMoa022457. N Engl J Med. 2003. PMID: 12637609 Free article. Clinical Trial.
Chronic myelogenous leukemia.
Druker BJ, O'Brien SG, Cortes J, Radich J. Druker BJ, et al. Among authors: o brien sg. Hematology Am Soc Hematol Educ Program. 2002:111-35. doi: 10.1182/asheducation-2002.1.111. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446421 Review.
Imatinib therapy in chronic myeloid leukemia.
Crossman LC, O'Brien SG. Crossman LC, et al. Among authors: o brien sg. Hematol Oncol Clin North Am. 2004 Jun;18(3):605-17, viii. doi: 10.1016/j.hoc.2004.03.014. Hematol Oncol Clin North Am. 2004. PMID: 15271395 Review.
Autografting in chronic myeloid leukaemia.
O'Brien SG, Goldman JM. O'Brien SG, et al. Blood Rev. 1994 Jun;8(2):63-9. doi: 10.1016/s0268-960x(05)80009-8. Blood Rev. 1994. PMID: 7950476 Review.
Managing cutaneous reactions to imatinib therapy.
Rule SA, O'Brien SG, Crossman LC. Rule SA, et al. Among authors: o brien sg. Blood. 2002 Nov 1;100(9):3434-5. doi: 10.1182/blood-2002-08-2431. Blood. 2002. PMID: 12412577 Free article. No abstract available.
Antisense therapeutics in haematological malignancies.
Kirkland MA, O'Brien SG, Goldman JM. Kirkland MA, et al. Among authors: o brien sg. Br J Haematol. 1994 Jul;87(3):447-52. doi: 10.1111/j.1365-2141.1994.tb08296.x. Br J Haematol. 1994. PMID: 7993784 Review. No abstract available.
63 results